MUMSS
REGN icon

Mitsubishi UFJ Morgan Stanley Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60
Closed -$43K – 157
2022
Q4 		$43K Sell
60
-60
-50% -$44.3K 0.38% 34
2022
Q3 		$83K Hold
120
– – 1.12% 15
2022
Q2 		$71K Hold
120
– – 0.1% 18
2022
Q1 		$84K Sell
120
-120
-50% -$75.9K 0.07% 13
2021
Q4 		$152K Buy
240
+10
+4% +$6.15K 0.07% 44
2021
Q3 		$139K Buy
230
+80
+53% +$49.7K 0.13% 20
2021
Q2 		$84K Buy
+150
New +$76K 0.62% 29
2014
Q4 		$41K Hold
100
– – 0.08% 60
2014
Q3 		$36K Hold
100
– – 0.1% 82
2014
Q2 		$28K Hold
100
– – 0.08% 96
2014
Q1 		$30K Sell
100
-110
-52% -$33.9K 0.08% 99
2013
Q4 		$58K Sell
210
-30
-13% -$8.63K 0.1% 47
2013
Q3 		$75K Buy
240
+90
+60% +$23.7K 0.12% 33
2013
Q2 		$34K Buy
+150
New +$34.9K 0.11% 110

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's REGN Position: Q1 2023 in Review

Mitsubishi UFJ Morgan Stanley Securities sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 60 shares — an estimated $43K sold.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in REGN in Q2 2013 and held it in 14 quarters. The position peaked at $152K in Q4 2021. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Mitsubishi UFJ Morgan Stanley Securities reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Mitsubishi UFJ Morgan Stanley Securities sold 60 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $43K.
  • Mitsubishi UFJ Morgan Stanley Securities first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Mitsubishi UFJ Morgan Stanley Securities's Regeneron Pharmaceuticals position peaked at $152K in Q4 2021.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q1 2023, filed 2 May 2023.